Status:
COMPLETED
A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
1. To evaluate the absorption and elimination of varenicline Formulation A transdermal delivery system \[TDS (patch)\] compared to varenicline immediate release tablet (CHANTIX®). 2. To evaluate the a...
Eligibility Criteria
Inclusion
- healthy adult smokers
Exclusion
- Significant blood, kidney, lung, gastrointestinal, heart, liver, psychiatric, or neurologic disease
- Illegal drug usage
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00661765
Start Date
April 1 2008
End Date
June 1 2008
Last Update
April 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Fargo, North Dakota, United States, 58104